MIT Team Builds Multicellular Integrated Brain Model

MIT scientists have developed a three-dimensional human brain tissue platform that integrates all major brain cell types, including neurons and glial cells, and vascular components into a single culture. These models, called Multicellular Integrated Brains (miBrains), are derived from donors’ induced pluripotent stem cells and mimic key structural and functional features of living brain tissue. The technology allows for customization, scalability, and patient-specific modeling, making it a powerful tool for both research and drug development.

Describing the work, Li-Huei Tsai, Picower senior author of the study in Proceedings of the National Academy of Sciences, said, “The miBrain is the only in vitro system that contains all six major cell types that are present in the human brain.” The team demonstrated its potential by using miBrains to reveal how a common genetic risk factor for Alzheimer’s disease influences pathological interactions between cells.

Each miBrain combines the accessibility of simple cell cultures with the complexity found in human tissue. The models self-assemble into functional units that include neurovascular structures, immune defenses, and nerve signaling components. Importantly, they possess a functioning blood-brain barrier that can regulate which substances enter the brain. Co-senior author Robert Langer noted that systems like miBrain could become critical. “Recent trends toward minimizing the use of animal models in drug development could make systems like this one increasingly important tools for discovering and developing new human drug targets.”

Two innovations enabled the development of miBrains: a hydrogel-based “neuromatrix” that replicates the brain’s extracellular environment, and an optimized mix of six brain cell types that form stable neurovascular units. Each cell type is cultured separately and can be genetically modified, allowing researchers to model specific neurological conditions. “Its highly modular design sets the miBrain apart, offering precise control over cellular inputs, genetic backgrounds, and sensors,” said study lead Alice Stanton.

The research team used miBrains to investigate the APOE4 gene variant, the strongest genetic predictor of Alzheimer’s disease. Their experiments showed that astrocytes carrying APOE4 generated disease-like changes only in the multicellular model, not when cultured alone. Further work demonstrated that communication between astrocytes and microglia was required for accumulation of phosphorylated tau, a protein linked to neurodegeneration. 

MIT researchers plan to refine miBrains by incorporating microfluidic flow and single-cell RNA sequencing to increase physiological realism. Stanton said the team aims to use the platform to pinpoint disease targets and evaluate therapy responses, while Tsai added, “I’m most excited by the possibility to create individualized miBrains for different individuals. This promises to pave the way for developing personalized medicine.”